Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1MI
|
|||
| Former ID |
DAP000950
|
|||
| Drug Name |
Mebendazole
|
|||
| Synonyms |
Bantenol; Banworm; Besantin; Lomper; MBDZ; Madicure; Mebendan; Mebendazol; Mebendazolum; Mebenoazole; Mebenvet; Mebex; Mebutar; Noverme; Ovitelmin; Pantelmin; Sqworm; Sufil; Surfont; Telmin; Vermicidin; Vermicol; Vermidil; Vermin; Vermirax; Vermox; Verpanyl; Versid; Wormkuur; Abello Farmacia Brand of Mebendazole; Anti Worm; Ardeypharm Brand of Mebendazole; Boots Brand of Mebendazole; Boots Threadworm Treatment; Diba Brand of Mebendazole; Elfar Brand of Mebendazole; Equivurm Plus; Esteve Brand of Mebendazole; Healthypharm Brand of Mebendazole; Janssen Brand of Mebendazole; Leidapharm Brand of Mebendazole; Norgine Brand of Mebendazole; Pfizer Brand of Mebendazole; Pripsen Mebendazole; SSL Brand of Mebendazole; Streger Brand of Mebendazole; Taxandria Brand of Mebendazole; Tedec Meiji Brand of Mebendazole; R 17635; R17635; Anti-Worm; Antiox (TN); Degort's Brand of Mebendazole; Mebendazol [INN-Spanish]; Mebendazole(USAN); Mebendazolum [INN-Latin]; Ovex (TN); Pripsen (TN); R 17,635; R-17635; Vermox (TN); MEBENDAZOLE, 99%; Mebendazole (JAN/USP); Mebendazole (JAN/USP/INN); Mebendazole [USAN:INN:BAN:JAN]; Methyl5-benzoyl benzimidazole-2-carbamate; Methyl 5-benzoyl-2-benzimidazolecarbamate; Methyl 5-benzoyl-2-benzimidazolylcarbamate; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Worm infection [ICD-11: 1F90.Z; ICD-9: 120-129] | Approved | [1] | |
| Therapeutic Class |
Antinematodal Agents
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H13N3O3
|
|||
| Canonical SMILES |
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
|
|||
| InChI |
1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)
|
|||
| InChIKey |
OPXLLQIJSORQAM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 31431-39-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
447580, 603018, 841968, 855610, 934559, 3206369, 3314033, 4782129, 7659513, 7847434, 7979874, 8149709, 8152521, 10321384, 10589234, 11109644, 11112718, 11139496, 11335926, 11361165, 11364192, 11366754, 11369316, 11372497, 11373851, 11377478, 11462137, 11466245, 11467365, 11485178, 11485890, 11489217, 11491254, 11492231, 11495112, 11500651, 14898153, 24870130, 24896742, 26612167, 26675660, 26680066, 26746927, 26746928, 29223141, 46508807, 47291163, 47365215, 47365216, 47589024
|
|||
| ChEBI ID |
CHEBI:6704
|
|||
| ADReCS Drug ID | BADD_D01353 | |||
| SuperDrug ATC ID |
P02CA01
|
|||
| SuperDrug CAS ID |
cas=031431397
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides cellulosilyticus DSM 14838
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides cellulosilyticus DSM 14838 (log2FC = -0.415; p = 0.039). | |||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.807; p = 0.002). | |||
|
Studied Microbe: Bacteroides eggerthii DSM20697
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides eggerthii DSM20697 (log2FC = -0.71; p = 0.029). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.799; p = 0.025). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.621; p = 0.005). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.752; p = 0.028). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.802; p = 0.007). | |||
|
Studied Microbe: Bacteroides stercoris ATCC 43183
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides stercoris ATCC 43183 (log2FC = -0.53; p = 0.023). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.426; p = 0.033). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.528; p = 0.021). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.864; p = 0.008). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.837; p = 0.038). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.69; p = 0.038). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Odoribacter splanchnicus (log2FC = -0.56; p = 0.041). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.674; p = 0.021). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bifidobacterium ruminantium (log2FC = -0.498; p = 0.008). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Bacteroides pectinophilus ATCC 43243
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Bacteroides pectinophilus ATCC 43243 (log2FC = -0.435; p = 0.005). | |||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.59; p = 0.049). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Mebendazole can be metabolized by Clostridium sp. (log2FC = -0.623; p = 0.025). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin beta (TUBB) | Target Info | Binder | [3] |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.